Results 161 to 170 of about 70,411 (245)

Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group

open access: yesHemaSphere, Volume 10, Issue 5, May 2026.
Abstract Relapse after chimeric antigen receptor (CAR) T‐cell therapy in large B‐cell lymphoma (LBCL) is associated with a dismal prognosis. Although Phase 3 trials have established CAR T‐cells as standard second‐line (2L) therapy, outcomes and optimal management after relapse in this setting remain unknown because no real‐world data are currently ...
Pierre Sesques   +37 more
wiley   +1 more source

Substrate recognition diversity and transport dynamics of ABCC1. [PDF]

open access: yesNat Commun
Sun P   +10 more
europepmc   +1 more source

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B‐Cell Lymphoma (CLSG‐CNS‐01): A Randomized, Multicenter, Prospective Phase 3 Trial

open access: yesHematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B‐cell lymphoma (DLBCL). Treatment consisted of six cycles of R‐CHOP + 2xR or DA‐EPOCH‐R + 2xR. Patients with intermediate or high‐risk
H. Mocikova   +12 more
wiley   +1 more source

From Platelet Toxicity to Precision Targeting: Evolving Strategies to Overcome Thrombocytopenia in BCL‐2/BCL‐XL Inhibition

open access: yesHealth Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Simultaneous blockade of the anti‐apoptotic proteins BCL‐2 and BCL‐XL has been shown to be efficacious in preclinical and clinical trials for tumors that are co‐dependent on their survival pathways, although clinical development has been limited owing to dose‐limiting thrombocytopenia associated with BCL‐XL inhibition.
Md Mohiuddin
wiley   +1 more source

MELAS‐Like Mitochondrial Encephalopathy With Catatonia Associated With a Pathogenic MT‐ND3 (m.10158 T > C) Mutation: A Case Report and Literature Review

open access: yesProgress in Neurology and Psychiatry, Volume 30, Issue 2, May 2026.
Abstract Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke‐like episodes (MELAS) is a rare multisystem mitochondrial disorder primarily caused by mutations in mitochondrial DNA. While it typically presents with stroke‐like episodes, seizures, and lactic acidosis, recent evidence highlights a broader clinical spectrum, including ...
Faezeh Khorshidian   +3 more
wiley   +1 more source

Japanese Clinical Practice Guidelines for Vascular Tumors, Vascular Malformations, Lymphatic Malformations, and Lymphangiomatosis 2022

open access: yesThe Journal of Dermatology, Volume 53, Issue 5, Page e257-e356, May 2026.
ABSTRACT The objective was to prepare guidelines to perform the current optimum treatment by organizing effective and efficient treatments of hemangiomas and vascular malformations, confirming the safety, and systematizing treatment, employing evidence‐based medicine techniques and aimed at improvement of the outcomes.
Yoshiaki Kinoshita   +116 more
wiley   +1 more source

Home - About - Disclaimer - Privacy